摘要
目的:探究活动性乙肝肝硬化患者长期治疗过程中通过替比夫定与阿德福韦酯联合治疗后取得的临床成效。方法:选取我院2015年1月-2016年6月入院的活动性乙肝肝硬化患者80例,随机分组法分为观察组和对照组,每一组40人。对照组治疗方法为阿德福韦酯治疗,观察组为替比夫定联合阿德福韦酯治疗。针对肝功能各指标水平、血清病毒学指标及不良反应发生情况,对两组进行对比分析。结果:在肝功能各指标水平方面,观察组均优于对照组(P<0.05);在HBV-DNA转阴率及HbeAg血清转阴率方面,观察组高于对照组(P<0.05);针对不良反应发生情况,观察组发生率(7.5%)与对照组(5%)相比无明显差异(P>0.05)。结论:活动性乙肝肝硬化患者长期治疗过程中通过替比夫定与阿德福韦酯联合治疗后取得的临床成效显著,能够有效改善患者肝功能指标水平,提高HBV-DNA转阴率及HbeAg血清转阴率,且不良反应发生率较低,应推广应用。
Objective: To explore the clinical efficacy of combination therapy of telbivudine and adefovir dipivoxil in patients with active hepatitis B cirrhosis during long-term treatment. Methods: 80 patients with active hepatitis B cirrhosis admitted to our hospital from January 2015 to June 2016 were randomly divided into observation group and control group, with 40 patients in each group. The control group was treated with adefovir dipivoxil, and the observation group was treated with telbivudine and adefovir dipivoxil. The level of liver function, the virological indexes and the incidence of adverse reactions were compared, and the two groups were compared and analyzed. Results: In the level of liver function, the observation group was better than the control group(P <0.05); in HBV-DNA negative rate and HbeAg seroconversion rate, the observation group was higher than the control group(P <0.05); There was no significant difference between the observation group(7.5%) and the control group(5%) in the incidence of adverse reactions(P> 0.05). Conclusion: The combination of telbivudine and adefovir dipivoxil in the treatment of patients with active hepatitis B cirrhosis has significant clinical efficacy and can improve the liver function index and improve HBV-DNA negative rate and HbeAg Serum negative rate, and the incidence of adverse reactions is low, should promote the use of.
出处
《中国妇幼健康研究》
2017年第S1期665-666,共2页
Chinese Journal of Woman and Child Health Research
